KOC
VRTX icon

Koss-Olinger Consulting’s Vertex Pharmaceuticals VRTX Stock Holding History

Koss-Olinger Consulting’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-646
Closed -$288K – 257
2026
Q1 		$288K Sell
646
-13
-2% -$6.06K 0.02% 215
2025
Q4 		$299K Sell
659
-298
-31% -$128K 0.02% 224
2025
Q3 		$426K Hold
957
– – 0.04% 227
2025
Q2 		$426K Sell
957
-41
-4% -$18.9K 0.04% 226
2025
Q1 		$484K Buy
+998
New +$465K 0.04% 206
2024
Q4 		– Sell
-896
Closed -$417K – 290
2024
Q3 		$417K Buy
896
+35
+4% +$16.8K 0.04% 183
2024
Q2 		$404K Buy
+861
New +$374K 0.04% 176
2024
Q1 		– Sell
-3,512
Closed -$1.43M – 310
2023
Q4 		$1.43M Sell
3,512
-393
-10% -$145K 0.14% 83
2023
Q3 		$1.36M Sell
3,905
-68
-2% -$23.8K 0.2% 65
2023
Q2 		$1.4M Hold
3,973
– – 0.16% 70
2023
Q1 		$1.25M Buy
3,973
+51
+1% +$15.3K 0.16% 74
2022
Q4 		$1.13M Sell
3,922
-2,931
-43% -$893K 0.16% 77
2022
Q3 		$1.98M Sell
6,853
-149
-2% -$42.9K 0.34% 25
2022
Q2 		$1.97M Sell
7,002
-1,346
-16% -$360K 0.36% 23
2022
Q1 		$2.18M Buy
8,348
+228
+3% +$54.1K 0.35% 24
2021
Q4 		$1.78M Buy
8,120
+4,355
+116% +$847K 0.27% 28
2021
Q3 		$683K Buy
+3,765
New +$735K 0.11% 91

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Koss-Olinger Consulting's VRTX Position: Q2 2026 in Review

Koss-Olinger Consulting sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 646 shares — an estimated $288K sold.

Koss-Olinger Consulting first reported a position in VRTX in Q3 2021 and held it in 17 quarters. The position peaked at $2.18M in Q1 2022. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Koss-Olinger Consulting reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Koss-Olinger Consulting sold 646 Vertex Pharmaceuticals shares in Q2 2026, an estimated $288K.
  • Koss-Olinger Consulting first reported a position in Vertex Pharmaceuticals in Q3 2021 and held it in 17 quarters.
  • Koss-Olinger Consulting's Vertex Pharmaceuticals position peaked at $2.18M in Q1 2022.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Koss-Olinger Consulting's 13F filing for Q2 2026, filed 10 Aug 2026.